// App-Quantinova.ai

: Prediction of response to neoadjuvant chemotherapy of patients with muscle invasive bladder cancer by molecular subtyping and antibody drug conjugate target gene quantitation: Preview of Bladder BRIDGister.

Researchers

Presenter

  • Ralph M. Wirtz

Principal Investigators

  • Paula Carolin Voss

  • Frank Friedersdorff

  • Dimitri Barski

  • Thomas Otto

  • Michael Waldner

  • Elke Veltrup

  • Friederike Linden

  • Meike Schwandt

  • Roland Hake

  • Sebastian Eidt

  • Jenny Roggisch

  • Constantin Rieger

  • Lucas Kastner

  • Axel Heidenreich

  • Stefan Koch

  • Thorsten H Ecke

Medical Centers

  • Department of Radiology, University Clinic of Cologne, Cologne, Germany

  • Institute of Pathology, St. Elisabeth-Krankenhaus Hohenlind, Cologne, Germany

  • STRATIFYER Molecular Pathology GmbH, Cologne, Germany

  • Dpt. of Urology, Charité - Universitätsmedizin Berlin, Berlin, Germany

  • Dpt. of Urology, HELIOS Hospital, Bad Saarow, Germany

  • Dpt of Urology, St. Elisabeth Hospital, Cologne, Germany

  • Dpt. of Urology, Rheinlandklinikum, Neuss, Germany

  • Dpt of Pathology, Helios Hospital, Bad Saarow, Germany

Locations

  • Germany

Companies

  • STRATIFYER Molecular

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Nectin Cell Adhesion Molecule 4

  • Proteasome Subunit Beta 8

  • Cytokeratin 20

  • Cytokeratin 5

  • Fibroblast growth factor receptor 1

Drug/Treatment

  • Cisplatin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved